RYAH Group (CSE: RYAH) today announced its entry into a memorandum of understanding (“MOU”) with Bazelet Pharma Ltd. and affiliates (together, “Bazelet”), the largest medical cannabis processing company in Israel, serving thousands of patients. According to the update, the collaboration is aimed at servicing Bazelet’s patients using RYAH Smart Inhalers and data analytics, once certified as a medical device in Israel, with the goal of providing safe and accurate patient inhalation therapies in plant medicine. “Bazelet brings extraordinary depth and expertise within a well-established and fast-growing medical cannabis market. We’re excited to be collaborating with Bazelet in bringing our smart inhaler and data analytics into this important region,” said Gregory Wagner, chief executive officer of RYAH.
In addition, RYAH provided an update to its previously announced non-brokered private placement of units of the company for aggregate gross proceeds of up to C$1,500,000, at an issue price of C$0.05 per unit (the “private placement”). As previously announced, each unit consists of (i) one Class A subordinate voting share of the company, and (ii) one share purchase warrant of the company (a “warrant”). Each warrant is exercisable for a period of 24 months at an exercise price of C$0.065. RYAH, on Jan. 21, 2022, closed the initial tranche of the private placement, with such tranche consisting of the issuance of an aggregate of 3,556,000 units for aggregate gross proceeds of C$177,800.
About RYAH Group Inc.
RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information, visit www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.